Twelve weeks of ledipasvir/sofosbuvir all‐oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials-Reference-Cited by-同舟云学术

Twelve weeks of ledipasvir/sofosbuvir all‐oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials

Published:2020-08-11 Issue:10 Volume:50 Page:1109-1117
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Asahina Yasuhiro¹,Liu Chun‐Jen²,Gane Edward³,Itoh Yoshito⁴,Kawada Norifumi⁵,Ueno Yoshiyuki⁶^ORCID,Youn Jin⁷,Wang Chen‐Yu⁷,Llewellyn Joe⁷,Matsuda Takuma⁷,Gaggar Anuj⁷,Mo Hongmei⁷,Dvory‐Sobol Hadas⁷,Crans Gerald⁷,Chuang Wan‐Long⁸,Chen Pei‐Jer²,Enomoto Nobuyuki⁹

Affiliation:

1. Department of Gastroenterology and Hepatology, Department of Liver Disease Control Tokyo Medical and Dental University Tokyo Japan

2. Department of Internal Medicine and Hepatitis Research Center National Taiwan University College of Medicine and Hospital Taipei City Taiwan

3. Department of Medicine University of Auckland Auckland New Zealand

4. Department of Gastroenterology and Hepatology Kyoto Prefectural University of Medicine Kyoto Japan

5. Department of Hepatology, Graduate School of Medicine Osaka City University Osaka Japan

6. Department of Gastroenterology Yamagata University Faculty of Medicine Yamagata Japan

7. Gilead Sciences Foster City California USA

8. Hepatobiliary Division, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung City Taiwan

9. First Department of Internal Medicine, Gastroenterology and Hepatology University of Yamanashi Yamanashi Japan

Funder

Gilead Sciences

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13546

Reference42 articles.

1. Systematic review: Asian patients with chronic hepatitis C infection

2. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective

3. Hepatocellular carcinoma in the Asia pacific region

4. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013

5. Treatment of chronic hepatitis C in Asia: When East meets West

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study;The Korean Journal of Internal Medicine;2022-11-01

2. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan;Journal of the Formosan Medical Association;2022-08

3. Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus;Hepatology Communications;2021-10-22

4. Reactivation of hepatitis C virus with severe hepatitis flare during steroid administration for interstitial pneumonia;Clinical Journal of Gastroenterology;2021-05-13

5. Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan;Liver International;2021-03-12